In contexts of crimes, disasters, terrorism or population displacement that presently occurs in Europe and numerous regions of the world, the necessity of having as soon as possible reliable, high throughput and real time analysis to identify individuals, victims and authors is a major societal and legal issue. The present MRSEI ForOnBoardLab project aspire to strengthen a multidisciplinary consortium which was federated, during a PhD thesis, around the theme of the rapid DNA analysis in the aim to structure a project for answering to the European H2020 call "SU-FCT02-2018-2019-2020: Technologies to enhance the fight against crime and terrorism, Sub-topic 1: [2019]; Trace qualification" at the beginning of 2019. The ambition of our European project is to set up a technological and normative European st of references, procedures and guidelines in the field of the genetic identification using high throughput DNA fingerprints, in real time and on site. In this way the project also aims at developing innovative biological collection devices and smart and on-board mobile laboratory in agreement with standards and reglementations and qualify and validated instruments and analytical methods. This in situ and real time forensic approach involves 9 academic, institutional and industrial partners from 6 European countries: France, Switzerland, Greece, Italy, Luxembourg, Belgium with intrernationaly recognized forensic leaders in DNA analysis performing more than 150 000 expertises by year. ForOnBoardLab aims to initiate and catalyse during 18 months the consortium to propose a structuring program in the H2020. Such a support of the French ANR within the framework of the AAP MRSEI will enhance the emergence of an European network in the field of biological sampling integrated into solutions of analysis high throughput , in situ and real time DNA including trainings and normative functions in a guides of recommanded practices to collect traces in complex crimes/disasters or major population migrations fields

PARC is an EU-wide research and innovation partnership programme to support EU and national chemical risk assessment and risk management bodies with new data, knowledge, methods, networks and skills to address current, emerging and novel chemical safety challenges. PARC will facilitate the transition to next generation risk assessment to better protect human health and the environment, in line with the Green Deal?s zero-pollution ambition for a toxic free environment and will be an enabler for the future EU ?Chemicals Strategy for Sustainability?. It builds in part on the work undertaken and experience acquired in past and on-going research and innovation actions, but goes beyond by its vocation to establish an EU-wide risk assessment hub of excellence. To contribute to several expected impacts of destination 2 ?Living and working in a health-promoting environment?, PARC will organise the activities to reach three specific objectives: - An EU-wide sustainable cross-disciplinary network to identify and agree on research and innovation needs and to support research uptake into regulatory chemical risk assessment. - Joint EU research and innovation activities responding to identified priorities in support of current regulatory risk assessment processes for chemical substances and to emerging challenges. - Strengthening existing capacities and building new transdisciplinary platforms to support chemical risk assessment. The Partnership brings together Ministries and national public health and risk assessment agencies, as well as research organisations and academia from almost all of EU Member States. Representatives of Directorates-General of the EC and EU agencies involved in the monitoring of chemicals and the assessment of risks are also participating. PARC will meet the needs of risk assessment agencies to better anticipate emerging risks and respond to the challenges and priorities of the new European policies.

The COVID-19 pandemic has confirmed and further highlighted the importance of planning and investing in research and innovation well before a health crisis occurs. For this purpose, the main goal of BE READY is to build a consolidated European Research and Innovation Area that provides the foundation of the candidate European partnership for pandemic preparedness so to improve the EU's preparedness to predict and respond to emerging health threats by better coordinating funding for research and innovation at EU, national (and regional) level towards common objectives and an agreed Strategic Research and Innovation Agenda. The Partnership is expected to build on existing pandemic preparedness networks, and work in synergy with the Health Emergency Response Authority (HERA), in close collaboration with ECDC, EMA and other relevant international and European actors. BE READY is composed by 24 organisations from 15 countries with complementary expertise and policy area ranging from Public Health Organisations, Ministries (of Science, University, Health, Innovation or Environment) and Research Performing Organisations that ensures a cross-cutting, interdisciplinary Global Health and One Health approach.

The END-VOC consortium will support the European and global response to the COVID-19 pandemic and Variants of Concern (VOC) through well characterised cohorts and linked with existing European and international initiatives. END-VOC consists of 19 partners in Europe (UK, Spain, Italy, Germany, Netherlands, Norway, Italy), South America (Brazil and Peru), Africa (Mozambique, South Africa, Nigeria and 13 ANTICOV African countries), Middle East (Palestine) and Asia (India, Pakistan, Philippines) with a focus on countries affected by VOCs and VOIs. We will elucidate the global circulation of the current and emerging SARS-CoV-2 VOCs and their characteristics, including transmissibility, pathogenicity and propensity to cause reinfection, to support best control strategies and the development of diagnostics; evaluate the impact of VOCs on the effectiveness of different vaccines and vaccination strategies; and assess the implications of VOCs on the choice of optimal treatment options. END-VOC will also investigate how VOCs alter long-term post-infection sequelae and where new VOCs emerge within hosts using our clinical cohorts. We will inform future preparedness and response working closely with international and national public health organisations and existing cohort consortia. Specific beyond state-of-the-art components of END-VOC include the use of novel phylogenetic prediction tools and mathematical modelling; generation of powerful cohorts through sentinel surveillance in low and middle income settings and cohorts of travellers to increase our global reach; use of novel predictive modelling of clinical outcomes by VOC and comorbidity/treatment and evaluation of differences in natural and vaccine immunity by VOC; antiviral screening models within cohorts and an artificial intelligence driven tool for the prediction of long COVID.

Air pollution, especially particulate matter (PM), and traffic noise are major intertwined environmental risks. They contribute to the incidence of cardiovascular, cerebrovascular, mental, and metabolic, so-called non-communicable diseases (NCDs). Air pollution contributes to annual premature deaths (0.5 million) and traffic noise to loss of 1.6 million healthy life years in Europe. Critical issues are that noise and PM are underrepresented in clinical guidelines and that European legal exposure limits exceed WHO standards, also due to a limited understanding of knowledge transfer and success metrics. Significant knowledge gaps are related to additive effects of PM and noise, the role of ultrafine particle (UFP), adverse brain-heart axis signaling, and the consequences for vulnerable groups such as high-risk patients and the elderly. We address these critical health issues of traffic noise and air pollution (PM incl. UFP) by a unique translational approach using experimental and computational models in clinical, interventional, and epidemiological studies. A primary goal is to identify disease-relevant biomarkers and understand the molecular pathways of cerebral, pulmonary and cardiovascular NCDs, also by effective translation of animal findings to human health. Our “bench to life” approach on brain-heart axis is entirely driven by profound preclinical mechanistic knowledge and will use novel Multiomics methodology (e.g. redox/phospho-proteomics, “spatial” epigenetics) allowing analysis of key pathomechanisms, to be included in exposure-response models. This will improve risk assessment and allow evaluation of the effectiveness of mitigation strategies. We will also consider the societal circumstances and policies at the national level and their impact on different stakeholders. MARKOPOLO will advance our understanding of the complex interplay between noise, air pollution, and human well-being and provide clearer information and guidelines for various stakeholders.